AIM Breakfasts

AIM BREAKFAST – 2nd September 2016

Set Menu AIM:

Total number of AIM Companies (Incl Susp): 1,006

Total number of AIM Companies trading: 993*
* As at 30 August 2016

Dish of the Day:

No primary today.

Off the Menu:

No AIM Leavers today

Set Menu ISDX Growth:

Total number of ISDX Growth Market Companies (Incl Susp): *

Total number of ISDX Growth Market Companies trading: *
* As at 30 August 2016

Dish of the Day:

Off the Menu:

What’s Cooking in the IPO Kitchen?

Misys— The press reports that the Banking Technology provider owned by Vista Equity Partners is seeking a £5.5bn float in London

Bacanora Lithium— To list on AIM around 28 Sep as holding company for TSX listed Bacanora Minerals at £100m market cap

Aura Energy—ASX listed uranium developer (ASX:AEE) expected to join AIM 6 September

Breakfast Buffet

Papua Mining (PML.L) 1.88p £1.59m

The company focused on the exploration and development of gold and copper deposits in Papua New Guinea  has announced a £400k subscription by Thalassa Holdings (THAL.L) at 1p. A separate offer is being made to qualifying shareholders to raise up to a further £400k at the same price. The proceeds  and any additional funds received by way of the Offer for Subscription will provide the Company with additional working capital and will enable Papua to continue to advance operations at the Company’s Mt Visi prospect.

Roxi Petroleum (RXP.L) 10p £93.74m

The Central Asian oil and gas company with a focus on Kazakhstan, has updated the market with news of a reserves update as at 31 December 2015 of BNG’s South Yelemes fields. The reserves update covers the Company’s shallow fields at its BNG asset and does not include its deeper prospects that are subject to drilling at its wells A5, A6 and 801. The company’s net entitlement in the field now totals a 17.1 MMBbl of Proved and Probable reserves rising to 26.3 MMBbl when including the possible category.

Fyffes (FFY.L) 132.25p £394.7m

The European importer and distributor of tropical produce has reported H1 Jun16 interims. Revenue up 14.7% to €739.3m. EBITDA up 11% to €44m. Diluted EPS up 0.8% to 10.01c. Dividend up 10% to 0.9032c.  FY Guidance reiterated. Adjusted EBITDA – €63m – €69m. Adjusted EBITA – €49m – €55m  Adjusted EPS – 12.8c – 14.5c, the mid point implying an 11.49x PE multiple. Completion of €99m acquisition of Highline Produce in period

Eckoh (ECK.L) 49p £117.3m

The global provider of secure payment products & customer contact solutions, announced a trading update regarding its US business & its faster than expected transition towards a pure SaaS pricing model. Over 80% of Eckoh’s US sales pipeline is already using this structure. This is expected to reduce the forecast margin from US Secure Payments in the short & medium term but to increase it in the longer term.  Consequently FY Mar17 PBT now expected below market expectations. Consensus is £5.3m. Medium/long term outlook remains positive.

ASOS (ASC.L) 4,562p £3.81bn

The global fashion destination for 20-somethings has reached a global settlement regarding trade mark infringement disputes with high-performance cycle wear manufacturer Assos of Switzerland GmbH, and German menswear retailer, Anson’s Herrenhaus KG. The disputes have resulted in several cases being heard in court, as well as multiple trade mark registry actions around the world.  The full and final settlement will cost ASOS £20.2m

Lifeline Scientific (LSIC.L) 309.5p £60.4m

The transplantation technology company, announced a trading update for H1Jun16. Revenues for transplantation products increase by 21.1% to $18.2m and sales of proprietary single-use consumables up 24.7% to $10.6m. Overshadowed by news of a merger led by Shanghai Genext Medical Technology for a cash consideration of US$87.8m or $4.08/share. Unanimous Board approval. Premium of 0.7% to yesterdays close but 51.3% prior to the strategic review announced 18 Sep 2015.

hVIVO (HVO.L) 181.5p £141.7m

The pioneer of human disease models, announced that the Company’s landmark asthma stratification initiative is now underway, with the first volunteer inoculated with human rhinovirus (HRV). The study seeks to discover a more effective way to differentiate subtypes of asthma patients – enabling the development of targeted therapies, disease biomarkers and more precision medicine-based approaches to asthma care. Over 80% of asthma attacks or exacerbations are caused by viruses, primarily HRV.

Sound Energy (SOU.L) 66.75p £357.8m

Sound Energy, the European and African focused upstream company, announced that, following Sound Energy’s inclusion in the FTSE AIM UK 50 Index with effect from Monday 19 September 2016, trading of the Company’s ordinary shares will be migrated to the London Stock Exchange’s SETS trading platform with effect from that same date. The Company’s ordinary shares have historically been traded via the London Stock Exchange’s SEAQ trading platform.

Trading Emissions (TRE.L) 2.58p £6.44m.

Trading Emissions has  announced the sale of a 11.52MW portion of its Italian solar portfolio to a member of the Sonnedix group. The aggregate net proceeds from the sale of the Investments, after allowing for transaction costs, are estimated to be EUR8.5 million. Staggered over two years.

Proxama (PROX.L) 0.52p £8.96m

The mobile proximity marketing expert, announced that on 1 September 2016 it was certified by Google to deliver Physical Web user experiences for consumers, after graduating from its new beacon certification programme.  Proxama is one of only two companies in the world & the first in Europe to be certified by Google as a Google Location Services Provider, offering services & experiences based around Google’s open beacon format, Eddystone. In FYDec2015 Proxama had £2.5m revenues and a £6m LBT.

Head Chef:

Derren Nathan
0203 764 2344
derren.nathan@hybridan.com

*A corporate client of Hybridan LLP

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX. If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.